Recently, Guanqiao Medical, a company specializing in the development of intelligent rehabilitation and assistive medical devices, announced the completion of a Series A financing round worth tens of millions of RMB. The round was led by a prominent healthcare-focused investment firm, with continued participation from several existing shareholders. The raised capital will primarily be used to accelerate clinical validation, regulatory approvals, and market commercialization of its core products, as well as to further strengthen R&D efforts in artificial intelligence and rehabilitation robotics.Founded in 2020, Guanqiao Medical is committed to enhancing the efficiency and accessibility of rehabilitation therapy through AI, IoT, and robotics technologies. The company has already launched several smart rehabilitation devices tailored for neurological and post-orthopedic surgery recovery scenarios. These products are currently being piloted in multiple top-tier hospitals across China and have received strong endorsements from clinical experts. The successful Series A funding underscores investors’ confidence in the company’s technological capabilities and commercial potential.As China’s aging population accelerates and demand for rehabilitation services grows, intelligent rehabilitation devices are emerging as a key focus area in medtech. Guanqiao Medical stated that it will continue to deepen its focus on specialized rehabilitation segments, drive product standardization, and scale deployment to support the high-quality development of China’s rehabilitation healthcare system.
近日，专注于智能康复与辅助医疗设备研发的管桥医疗（Guanqiao Medical）宣布完成数千万元人民币的A轮融资。本轮融资由知名医疗健康领域投资机构领投，多家老股东持续跟投。所募资金将主要用于加速其核心产品的临床验证、注册申报及市场推广，并进一步加强在人工智能与康复机器人技术方面的研发投入。管桥医疗成立于2020年，致力于通过AI、物联网和机器人技术提升康复治疗的效率与可及性。公司目前已推出多款面向神经康复、骨科术后康复等场景的智能康复设备，产品已在多家三甲医院开展试点应用，获得临床专家的高度认可。此次A轮融资的成功，标志着资本市场对其技术实力与商业化前景的高度看好。随着中国老龄化社会加速到来以及康复医疗需求持续增长，智能康复设备正成为医疗科技领域的热点赛道。管桥医疗表示，未来将持续深耕康复医疗细分领域，推动产品标准化与规模化落地，助力中国康复医疗体系高质量发展。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/10675.html